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Abstract 
 
Colorectal cancer is the third most commonly diagnosed cancer in men and the second 
in women, and represents one of the leading causes of cancer-related deaths. Despite 
progresses in treatment options, prognosis for advanced disease with recurrence and 
metastasis is still poor, emphasizing the need for new therapeutic strategies. 
In recent years, increasing knowledge about the interaction between the immune system 
and tumour cells, as well as about the tumour microenvironment, led to the development 
of novel anti-cancer approaches globally known as cancer immunotherapy. 
Immunotherapies are designed to enhance antitumour immune response and to avoid 
immunosuppression, and comprise several different strategies like cancer vaccines, 
adoptive T-cell therapy and immune checkpoint inhibitors. Recently, the use of 
checkpoint inhibitors such as specific antibodies for cytotoxic T lymphocyte-associated 
antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have shown to be an 
effective treatment in several types of cancers. Although the importance of the immune 
system in colorectal cancer has already been recognized, the potential significance of 
immunotherapy in this cancer is still at an early stage. Currently, several 
immunotherapeutic approaches, particularly those with immune checkpoints inhibitors, 
are being evaluated in various clinical trials.  
This paper reviews the most relevant clinical data concerning such immunotherapeutic 
approaches for colorectal cancer, pointing out their possible advantages and 
disadvantages. 
Despite the research using different immunotherapy strategies in the treatment of 
colorectal cancer, thus far none has been approved for use in clinical practice. The most 
promising results have been achieved in the subset of patients with microsatellite 
instable tumours using an immune checkpoint inhibitor; however, the majority of patients 
have microsatellite stable cancers. Therefore, several clinical trials are in progress, either 
with single agents or via combination regimens, to test whether viable treatment options 
arise. 
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Resumo 
 
O cancro colorretal é o terceiro tipo de cancro mais diagnosticado nos homens e o 
segundo nas mulheres, e representa uma das principais causas de morte relacionadas 
com o cancro. Apesar dos avanços obtidos nas opções terapêuticas, o prognóstico nos 
casos de doença avançada ainda é fraco, o que demonstra a necessidade de novas 
estratégias terapêuticas.  
Nos últimos anos, o conhecimento crescente sobre a interação entre o sistema 
imunitário e as células tumorais, bem como sobre o microambiente tumoral, levou ao 
desenvolvimento de novas estratégias no combate ao cancro, genericamente 
conhecidas como imunoterapia oncológica. As imunoterapias têm como objetivo 
aumentar a resposta imunitária antitumoral e evitar a imunossupressão, e incluem 
opções como vacinas, terapia adoptiva com células T, e inibidores de checkpoints 
imunológicos. Recentemente, o uso destes inibidores, com anticorpos para o antigénio 
4 associado a linfócitos T citotóxicos (CTLA-4) e para a proteína de morte celular 
programada 1 (PD-1), revelou ser eficaz em vários tipos de cancro. Embora a 
importância do sistema imunitário no cancro colorretal já tenha sido reconhecida, a 
relevância da imunoterapia neste tipo de cancro ainda se encontra numa fase inicial. 
Atualmente, vários ensaios clínicos estão a ser realizados, particularmente com 
inibidores de checkpoints imunológicos, para avaliar a eficácia destas terapêuticas.  
Este artigo tem como objetivo fazer uma revisão dos resultados clínicos mais relevantes 
no que diz respeito às diferentes imunoterapias em estudo no cancro colorretal, 
salientando as suas possíveis vantagens e desvantagens.  
Apesar da investigação feita com diferentes estratégias imunoterapêuticas nos doentes 
com cancro colorretal, até ao momento nenhuma delas foi aprovada para uso na prática 
clínica. Os resultados mais promissores foram obtidos no subgrupo de doentes com 
tumores com instabilidade de microssatélites utilizando um inibidor de checkpoint 
imunológico; porém, a maioria dos doentes apresenta tumores com estabilidade de 
microssatélites. Vários ensaios clínicos estão a ser realizados, quer com agentes 
isolados quer com regimes combinados, para avaliar novas opções de tratamento. 
 
 
 
 
Palavras-chave: imunoterapia, cancro colorretal, inibidores de checkpoints 
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1. Introduction 
 
1.1 Epidemiology 
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in men (746,000 
cases, 10.0% of the total) and the second in women (614,000 cases, 9.2% of the total) 
worldwide. Variations in incidence rates are observed across the world, with the highest 
rates in Australia/New Zealand and lowest in West Africa; mortality rates present less 
variability, with highest rates in Central and Eastern Europe and lowest in Western Africa 
(Ferlay et al., 2015). 
In the United States (US) in 2017, the estimated number of newly diagnosed individuals 
with CRC is 135,430 and the estimated number of deaths from the disease is 50,260. 
Although most of the cases (58%) are diagnosed in people of 65 years or older, 39% of 
women and 45% of men are younger than that (Siegel et al., 2017a). A downward trend 
in mortality rates has been observed in the last decades in US, falling 51% from 1976 to 
2014 (28.6 to 14.1 per 100,000 cases) (Siegel et al., 2017a). Similarly, most European 
countries have also experienced a decline in CRC mortality, with the average rate 
dropping from 35.3 to 31.3 deaths per 100,000 between 2003 and 2013 (OECD/EU, 
2016). Mortality reductions are attributed to changes in risk factors (e.g. diet and life-style 
related aspects such as smoking and alcohol consumption), the introduction of screening 
tests, and improvements in treatment (OECD/EU, 2016). In spite of that, CRC is still one 
of the most common cause of cancer-related death both in men and women. In fact, 
although 39% of the patients are diagnosed with localized CRC, for whom the 5-year 
relative survival rate is 90%, about 25% of patients present with metastases at diagnosis 
and almost half of the patients will develop metastases during the course of the disease 
(Van Cutsem et al., 2014; Siegel et al., 2017b). Current treatment for metastatic CRC is 
generally based on cytotoxic chemotherapy regimens in combination with targeted 
therapies (e.g. anti-EGFR antibodies). Despite progress in treatment options, 5-year 
relative survival rate decreases to 71% and 14% for patients diagnosed with regional 
and distant metastasis, respectively (Siegel et al., 2017b).  
Thus, prognosis for patients with advanced disease is still poor, highlighting the need of 
novel therapeutic strategies. 
 
1.2 Molecular Basis of Colorectal Cancer  
Colorectal cancer occurs in three different patterns: sporadic, familial and inherited. The 
sporadic form accounts for most of CRC cases (~70%) and derives from somatic 
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mutations. Inherited CRC occurs in 10% of cases and comprises cancer predisposition 
syndromes such as Lynch Syndrome and Familial Adenomatous Polyposis (FAP), 
whereas familial CRC accounts for 25 % of CRCs and presents without precisely defined 
Mendelian inheritance patterns or genetic etiology (Roper & Hung, 2013).  
Different molecular mechanisms can give rise to CRC, namely chromosomal instability 
(CIN), microsatellite instability (MSI), and CpG island methylator phenotype (CIMP) 
(Tariq & Ghias, 2016). Most of CRCs (65-70%) arise via the CIN pathway, which is 
characterized by aneuploidy and loss of heterozygosity. Microsatellite instability, found 
in about 15% of all CRCs, is characterized by length alterations in repetitive DNA regions 
called microsatellites, and derives from defects in the DNA mismatch repair (MMR) 
system (Tariq & Ghias, 2016). Most MSI CRCs are sporadic cases due to 
hypermethylation of MLH1 gene promotor, whereas 3% are caused by germline 
mutations in MSH2, MSH6, MLH1 and PMS2 genes or EpCAM deletion, causing Lynch 
syndrome (Zhang & Li, 2013). The CIMP pathway is characterized by promoter 
hypermethylation of various tumour suppressor genes. These three mechanisms, 
however, are not mutually exclusive, as tumours can sometimes demonstrate features 
of multiple pathways (Tariq & Ghias, 2016). 
The different pathways are associated with distinct clinical features and pathologic 
behavior. Indeed, MSI tumours are often associated with the proximal colon, have higher 
levels of tumour-infiltrating lymphocytes (TIL) and are associated with a better prognosis 
(Smyrk et al., 2001; Benatti et al., 2005). 
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2. Objectives 
 
The conventional treatments for advanced CRC cancer, including radiation, 
chemotherapy and targeted agents are designed to act directly on tumours, inhibiting 
their growth or destroying them. However, resistance to these therapies eventually 
develops and toxicities may limit their administration at effective levels. These facts 
highlight the need to develop alternative strategies in order to prolong patients’ survival. 
In this context, immunotherapy is emerging as a promising approach in oncology, 
intended to stimulate and enhance the ability of a patient’s immune system to recognize 
and destroy tumours. Cancer immunotherapies may therefore overcome some of the 
resistance mechanisms that occur with traditional agents. 
Immunotherapy strategies are currently therapeutic options in several types of cancer, 
including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma. It 
remains however in the experimental field in the case of CRC. 
This paper reviews the antitumour immune response and the most relevant 
immunotherapeutic approaches under investigation in CRC, such as cancer vaccines, 
adoptive T-cell therapy, and immune checkpoint inhibitors.  
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3. Material and Methods 
 
References for this review were identified by searches of PubMed database using the 
keywords: “immunotherapy”, “colorectal cancer”, “cancer vaccines”, and “immune 
checkpoints”. The selection of articles was based on the relevance to the topic of the 
review, date of publication, and journal’s impact factor. In addition, further articles were 
identified from references of selected studies. 
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4. Results 
 
4.1 The immune system and cancer 
The immune system primarily functions to protect the host from damage caused by 
pathogens, but it has also the ability to recognize and destroy cancer cells based on their 
expression of tumour antigens, in a process historically known as cancer 
immunosurveillance. However, it is now well established that the immune system can 
have a dual role in cancer development and progression. In fact, although it can inhibit 
tumour growth by destroying malignant cells, it can also promote its progression either 
by selecting tumour cells with reduced immunogenicity or by establishing conditions 
within the tumour microenvironment that facilitate tumour outgrowth (Schreiber et al., 
2011). These findings prompted the refinement of the immunosurveillance concept to the 
formulation of the cancer immunoediting hypothesis, which refers to a dynamic process 
including three distinct phases: elimination, equilibrium, and escape. Elimination refers 
to cancer immunosurveillance, in which innate and adaptive immune systems cooperate 
to detect an emerging tumour and destroy it before it turns clinically visible. In spite of 
that, some tumour cells may still persist and enter an equilibrium phase, in which they 
co-exist with the effector cells of the immune system in a state of tumour dormancy. 
During this phase, the immune system restricts outgrowth of malignant cells but also 
shapes their immunogenicity by selecting for less immunogenic variants. These cells 
eventually acquire the ability to evade immune recognition and destruction, allowing 
tumour progression and clinical expression. This represents the last step in the 
immunoediting process, known as the escape phase (Schreiber et al., 2011). 
 
To mount an effective antitumour immune response several different processes are 
required. First, dendritic cells (DSs) must capture and process tumour antigens and 
present them on MHC class I and class II molecules. In the presence of appropriate 
activation and/or maturation signals, DCs will differentiate and migrate to lymph nodes 
where they present these antigens to naïve T-cells. This leads to priming and activation 
of effector T-cells against tumour-specific antigens. Finally, the activated effector T-cells 
traffic to and infiltrate the tumour, specifically recognizing and binding to tumour cells 
through the interaction between its T-cell receptor (TCR) and its cognate antigen bound 
to MHC class I, ultimately destroying target cancer cells (Figure 1) (Chen & Mellman, 
2013). 
Nevertheless, malignant cells can exploit numerous mechanisms to evade recognition 
and destruction by the immune system. One of these mechanisms is the ineffective 
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presentation of antigens to immune cells by reducing the expression of MHC class I 
molecules in the cell surface, which have been associated with a poor prognosis in CRCs 
(Watson et al., 2006). Recruitment of immunosuppressive cells (regulatory T-cells - 
Tregs, and myeloid-derived suppressor cells - MDSCs) is also an important mechanism 
of escape from the host immune system. In normal physiologic conditions, Tregs prevent 
autoimmunity disorders by secreting immunosuppressive cytokines. In cancer patients, 
however, Treg can block immune response against cancer cells and therefore Treg 
infiltration of tumours is generally associated with a poor outcome (Halvorsen et al., 
2014), although contradictory results have been reported in CRC (Clarke et al., 2006; 
Ling et al., 2007; Salama et al., 2009; Frey et al., 2010). In addition, it was demonstrated 
that CRC patients have high levels of MDSCs in the primary tumour and in peripheral 
blood, which also correlates with advanced disease stages and lymph node metastases 
(OuYang et al., 2015). Other escape strategy includes the dysregulation of T-cell activity. 
This can occur either by the activation of inhibitory pathways (known as immune 
checkpoints), such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and 
programmed cell death protein 1 (PD-1), or through the inhibition of T-cell activation 
pathways, for example CD137, OX-40, CD40, GITR, and HVEM (Pennock & Chow, 
2015). A deep understanding of these escape mechanisms is essential and must be 
taken into consideration in the development of novel immunotherapeutic strategies. 
As previously mentioned, there is an increasing body of evidence suggesting that 
immune cells play a significant role in tumours progression. Indeed, high lymphocytic 
infiltration has been associated with favorable clinical outcome in several types of 
tumours, such as melanoma, head and neck, breast, renal, prostate and lung cancer 
(Fridman et al., 2012). In line with these data, Galon et al. (2006) have also demonstrated 
that CRC patients without recurrence had higher immune cell densities in the center and 
in the invasive margin of the tumour than patients whose cancer had recurred. The 
authors concluded that the level of lymphocytic infiltration within the tumour is a strong 
prognostic factor that predicts recurrence and longer overall survival (Galon et al., 2006). 
Subsequent studies reported similar results, reinforcing the importance of immunity in 
this type of cancer (Ogino et al., 2009; Mlecnik et al., 2011).    
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Figure 1: Phases in the development of a cellular immune response against tumour 
antigens. The antitumour immune response is initiated by immature DCs, which capture and 
process tumour antigens and present them on MHC class I and MHC class II molecules. DCs 
then migrate to tumor-draining lymph nodes where they present tumour antigens to naïve 
T-cells. Activation of T-cells involves not only the interaction between the antigen–MHC 
complex on DCs and TCRs, but also costimulatory molecules. The immune response 
proceeds with the infiltration of activated cytotoxic T-cells into the tumour, eventually killing 
malignant cells. CTL, cytotoxic T-cell; DC, dendritic cell; MDSC, myeloid-derived suppressor cell; MHC, 
major histocompatibility complex; TCR, T-cell receptor; TH1, type 1 T helper cells; TREG, regulatory 
T-cells. Adapted from Melero et al. (2014). 
 
 
 
4.2 Immunotherapy in Colorectal Cancer  
Cancer immunotherapy is a therapeutic approach designed to generate or enhance a 
host immune response against malignant cells, and include active, passive or 
immunomodulatory strategies. Whereas active immunotherapy increases the ability of 
patient’s immune system to generate effective antitumour immune responses, passive 
immunotherapy involves the administration of immunologic effectors to patients, such as 
lymphocytes or antibodies, to mediate an immune response. Immunomodulatory agents, 
in turn, improve general immune responsiveness and are intended to increase 
antitumour immune responses, but are not targeted at specific antigens (Melero et al., 
2014). 
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Several immunotherapy strategies for treatment of CRC patients are currently under 
research in clinical trials, including cancer vaccines, adoptive T-cell therapy, and immune 
checkpoint inhibitors, as described in the following sections.  
 
4.2.1 Cancer vaccines 
Cancer vaccines are active therapeutic approaches used to generate immunologic 
responses against tumour cells through the induction of effective cellular and humoral 
responses. Cancer vaccines require dendritic cell activation and presentation of the 
targeted tumour antigens to T-cells in order to establish an immune response. 
The most important types of cancer vaccines include autologous tumour cell vaccines, 
peptide vaccines, dendritic cell vaccines, and viral-vector vaccines.  
 
Autologous Tumour Cell Vaccines 
Autologous tumour cell vaccines are derived from cancer cells isolated from a patient, 
which are processed ex vivo to a vaccine formulation and then re-administered to the 
patient, usually in combination with an adjuvant immunostimulant. Typically, these 
vaccines are produced after surgical resection of the tumour, which is irradiated or 
treated with reagents to create an inactive lysate (Patel et al., 2014). Whole tumour cell 
vaccines have the advantage of comprising all tumour antigens, so they can potentially 
induce adaptive antitumour immunity against several antigens. However, these vaccines 
are specific to each patient and their preparation is relatively costly and time consuming. 
Furthermore, it has been demonstrated that the expression level of tumour-associated 
antigens by tumour cell vaccines is probably lower than that of other vaccine types, 
resulting therefore in a less effective immune response (Xiang et al., 2013). 
Whole cancer cell vaccines have shown some promise in CRC. OncoVax, an irradiated 
autologous tumour-cell vaccine with bacillus Calmette-Guérin (BCG) adjuvant, is one of 
the most intensively studied in CRC. Harris et al. (2000) have conducted a phase III 
clinical trial with an autologous tumour cell–BCG vaccine in stage II (n=297) and stage 
III (n=115) colon cancer patients to determine if surgical resection combined with active 
specific immunotherapy (ASI) was more beneficial than resection alone. Results did not 
show a statistically significant difference in disease-free survival (DFS) and overall 
survival (OS) between groups. However, patients with delayed-type hypersensitivity 
(DTH) reaction had increased 5-year survival which correlated with the order of the 
induration response, suggesting that patients who develop a greater local reaction may 
benefit from the vaccine (Harris et al., 2000). A similar study also in stage II and III colon 
cancer patients (n=254) using OncoVAX in an adjuvant setting demonstrated a clinical 
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benefit only in stage II patients, with a significant longer recurrence-free interval (RFI) 
and 61% risk reduction for recurrences (Vermorken et al., 1999). Using part of this cohort 
of patients, de Weger et al. (2012) investigated whether the beneficial effects correlate 
with microsatellite status of the primary tumour. The analysis revealed that patients with 
microsatellite stable stage II tumours who received adjuvant vaccine treatment had a 
significant improved recurrence-free survival (RFS) as compared to controls. In addition, 
patient group with microsatellite instability did well overall, irrespective of tumour stage 
and treatment arm (de Weger et al., 2012). 
Hanna et al. (2001) performed a meta-analysis of three phase III studies using OncoVAX 
again in stages II and III colon cancer patients. In the three studies, patients were 
randomized either to a vaccine-treatment arm or to a control arm after surgical resection 
of the primary tumour. The results showed that OncoVAX-treated patients had a 
significant improvement in RFI and in RFS. The beneficial effect in these clinical 
outcomes was superior in stage II patients. A confirmatory phase IIIb clinical trial in 
patients with stage II colon cancer is currently ongoing (NCT02448173). 
In addition to BCG, autologous CRC vaccines have also been produced using Newcastle 
disease virus (ATV-NDV). A phase III trial evaluated the clinical efficacy of ATV-NDV 
after resection of liver metastasis from CRC (n=50). Although no differences in the OS, 
DFS and metastases-free survival (MFS) were observed between the immunized and 
control CRC groups, a significant advantage for vaccinated colon cancer patients (not 
for rectal cancer patients) was observed with respect to OS and MFS (Schulze et al., 
2009). 
To date, research concerning autologous cell vaccines in CRC has shown modest 
clinical activity. The small proportion of tumour-specific antigens expressed by cancer 
cells and the generally poorly immunogenicity of these type of vaccines can explain, at 
least in part, the moderate results obtained in most trials (Signorini et al., 2016). 
 
Peptide Vaccines 
Peptide vaccines are based on the identification and synthesis of epitopes unique to 
cancer cells which can induce tumour antigen-specific immune responses. These 
vaccines have therefore the potential to generate a more specific antitumour response 
when compared to autologous tumour cell vaccines. Although considered simple, safe, 
economical and able to target tumour-specific antigens, peptide vaccines have some 
disadvantages that have restricted their effectiveness. These include poor 
immunogenicity, HLA-restriction limiting the peptide vaccines to specific HLA haplotypes, 
cancer recurrence due to antigenic escape and an excessively long lag between the first 
infusion and the clinically relevant response (Signorini et al., 2016). 
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Several tumour-associated antigens have been targeted by peptide vaccines in CRC 
including carcinoembryonic antigen (CEA), mucin 1, β-human chorionic gonadotropin (β-
hCG), EpCAM, 5T4, EpHA2, gastrin, survivin, SART3, and p53 (Patel et al., 2014). 
Phase I clinical trials have generally shown that these vaccines are safe and able to elicit 
antigen-specific immune responses.  
More recently, Okuno et al. (2011) used a peptide vaccine derived from ring finger protein 
43 (RNF43) and 34-kDa translocase of the outer mitochondrial membrane (TOMM34) 
that was administered in combination with chemotherapy in patients with metastatic 
CRC. Cytotoxic T lymphocyte (CTL) responses were induced against one or both 
antigens in 57% (12/21) and 38% (8/21) of the patients, respectively. Interestingly, 
patients with CTL responses against both antigens had the longest survival, followed by 
patients who developed a response to one peptide.  
Additional phase II and III trials are needed to establish the efficacy of peptide vaccines 
in CRC treatment. 
 
Dendritic cell vaccines 
As previously mentioned, DCs are potent antigen-presenting cells (APC) and also 
express costimulatory molecules necessary for an effective immune response. It is 
therefore expected that DC vaccines are able to elicit antitumour immune responses 
against tumour-specific antigens. A DC-based cancer vaccine (Sipuleucel-T) has been 
approved by FDA for the treatment of metastatic castrate-resistance prostate cancer, 
demonstrating the potential of this approach (Cheever & Higano, 2011). 
Several strategies have been used to deliver tumour antigens ex vivo to DC, including 
pulsing DC with synthetic peptides derived from tumour-associated antigens, tumour cell 
lysates, apoptotic tumour cells, tumour RNA, and physically fuse DCs with whole tumour 
cells (Signorini et al., 2016). The selection of the tumour antigens to be loaded in DC is 
a critical step to achieve best clinical results.  
In CRC, previous studies have shown that CEA-DC vaccines are safe, well tolerated and 
able to induce a CEA-specific immune response (Morse et al., 1999; Fong et al., 2001; 
Itoh et al., 2002; Lesterhuis et al., 2006). A phase II study evaluated the clinical benefit 
of a DC vaccine consisting of autologous DCs pulsed with allogenic melanoma cell lysate 
in patients with advanced CRC expressing MAGE-antigens (Toh et al., 2009). Twenty 
patients were included in the study and 17 of them received immunizations: one patient 
experienced a partial response and seven achieved stable disease, representing a 
clinical benefit rate of 40%. The median OS from inclusion was 7.4 months and the 
median progression-free survival (PFS) was 3.4 months. Five patients (25%) 
experienced a prolonged PFS for more than 6 months. Using a similar vaccine, Burgdorf 
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et al. (2008) performed a study in patients with advanced CRC who had no indication for 
further treatments (radio-, chemo- or surgical therapy). The clinical responses were 
limited: no partial or complete responses were observed; 4 patients (out of 17) achieved 
stable disease, of which two remained stable through the entire study period, rendering 
a clinical benefit rate of 24%. 
More recently, the clinical benefit of a DC vaccine combined with cytokine-induced killer 
cells (CIK) was assessed in a study with CRC patients (n=13) disease-free after surgical 
resection and chemo/radiotherapy (Gao et al., 2014). The results demonstrated a 
significantly prolonged DFS and OS in CRC patients of the treatment group compared 
to the CRC controls (5-year DFS rate: 66% vs 8%; OS rate: 75% vs 15%; P<0.01). 
Despite the small patient cohort, these data demonstrate that the DC-CIK vaccine might 
be a useful approach to improve survival and tumour recurrence rates in post-surgical 
CRC patients (Gao et al., 2014). 
 
Viral-vector vaccines 
Viral vectors can be genetically modified to express tumour antigens to produce cancer 
vaccines, taking advantage of the natural immunogenicity of the viruses that acts as 
adjuvant to improve the immune response (Signorini et al., 2016). These vaccines 
include viruses with high transfection efficiency and immunostimulatory capacity such as 
lentiviruses, poxviruses, adenoviruses and retroviruses. As disadvantages, viral-vector 
vaccines are expensive, potentially pathogenic and can lead to insertional mutagenesis 
(Xiang et al., 2013). 
Several virus-based vaccines have been tested in CRC patients, of which the most 
significant are described below: 
 
 ALVAC is a nonreplicating canarypox virus modified to express CEA and sometimes 
also B7.1 costimulatory molecule, which has been used in CRC patients. A phase I 
trial showed that ALVAC expressing CEA was safe and resulted in increased 
CEA-specific T-cell responses (Marshall et al., 1999). More recently, Kaufman et al. 
(2008) performed a phase II trial in patients with metastatic CRC to assess the effect 
of chemotherapy on ALVAC-CEA/B7.1. Patients were randomized to receive either 
ALVAC before and concomitantly with chemotherapy (n=39), ALVAC with tetanus 
adjuvant before and concomitantly with chemotherapy (n=40), or chemotherapy 
followed by ALVAC (n=39). The results demonstrated that all patients developed 
antibody responses against ALVAC, but increased anti-CEA antibody titers were 
detected in only three patients, and increases in CEA-specific T-cells was detected 
in 30% to 50% of the patients. In addition, objective clinical responses were observed 
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in 40% of the vaccinated patients. Overall, there were no differences in clinical or 
immune responses between the treatment groups. Therefore, this study 
demonstrated that systemic chemotherapy did not affect vaccine-mediated immunity. 
 
 TroVax is a highly-attenuated strain of vaccinia virus encoding the human oncofetal 
antigen 5T4. The 5T4 antigen is rarely detected on normal tissues and is expressed 
at high levels on trophoblastic cells and most adenocarcinomas, including CRC, in 
which it is associated with poor prognosis (Starzynska et al., 1994). A phase I study 
in patients with advanced CRC demonstrated that TroVax was well tolerated and 
able to induce anti-5T4 cellular and humoral immune responses. In addition, a 
positive association was found between the development of 5T4 antibodies and 
patient survival or time to disease progression (Harrop et al., 2006). In a different 
study, Elkord et al. (2008) administered TroVax to CRC patients, pre- and post-
surgical resection of liver metastases. Most patients developed a 5T4-specific 
cellular and/or humoral responses, and patients with above median 5T4-specific 
antibody responses tend to survive longer than those with below median responses, 
although this difference was not statistically significant. TroVax has also been 
evaluated alongside two different chemotherapy regimens in CRC patients, 
establishing its safety and ability to induce specific immune responses without 
increased toxicity (Harrop et al., 2007; Harrop et al., 2008). 
 
 PANVAC is a recombinant poxvirus based vector encoding CEA, MUC1, and three 
costimulatory molecules (ICAM-1; LFA-3; B7.1). In a phase II trial by Morse et al. 
(2013b), patients with metastatic CRC, disease-free after metastectomy and 
perioperative chemotherapy, were randomized to immunization either with DC 
modified with PANVAC (DC/PANVAC) or PANVAC with GM-CSF 
(PANVAC/GM-CSF). No significant differences in PFS and OS were observed 
between the two vaccine strategies, but vaccinated patients as a group exhibited 
prolonged survival compared to unvaccinated controls (Morse et al., 2013b). 
Similarly, a fowlpox virus-vector vaccine also expressing CEA, MUC1, and three 
costimulatory molecules (TRICOM: ICAM-1; LFA-3; B7.1) has been tested in patients 
with different CEA expressing tumours, including 35 patients with advanced CRC. 
The results demonstrated that this vaccine was safe and induced CEA-specific T-cell 
response in most of the patients, as well as stabilization of disease in 40% patients 
for at least 4 months (Marshall et al., 2005).  
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 An adenoviral vector encoding the CEA antigen, Ad5 [E1-, E2b-]-CEA(6D), has been 
studied in a phase I/II clinical trial and shown to induce cell-mediated immunity in 
61% of the patients with advanced CRC. The efficacy of Ad5 vaccines can be limited 
by pre-existing Ad5-specific neutralizing antibodies; however, OS (48% at 12 
months) was similar across patients regardless of pre-existing Ad5 neutralizing 
antibody titres (Morse et al., 2013a). 
 
4.2.2 Adoptive T-cell Therapy 
Adoptive T-cell therapy is a form of passive immunotherapy that involves the isolation of 
autologous T-cells with antitumour activity, their activation and expansion to large 
numbers ex vivo, and their re-infusion into the patient, frequently together with IL-2. In 
most cases, lymphodepleting regimens are used prior to cells administration given their 
association with an increase persistence of the transferred T-cells (Restifo et al., 2012).  
An important advantage of this therapy is that T-cells are activated ex vivo so some the 
immunosuppressive factors that occur in vivo are overcome. On the other hand, 
limitations of this approach include possible lack of immune memory, reduced 
persistence of adoptive T-cells in vivo, high costs, and extensive time required to prepare 
T-cells, in addition to the risk of severe adverse effects (Xiang et al., 2013). 
Adoptive T-cell therapy with autologous TILs has been shown to be an effective 
immunotherapy to induce complete durable responses in patients with metastatic 
melanoma (Rosenberg et al., 2011).The effectiveness of this approach has also been 
investigated in CRC patients in some previous studies. In a clinical trial performed by 
Gardini et al. (2004), 14 patients received adjuvant immunotherapy with TILs in 
combination with IL-2 after resection of liver metastasis from CRC. The results did not 
demonstrate a significant improved long-term survival or reduced risk of recurrence 
compared to the control group (Gardini et al., 2004). 
Adoptive T-cell therapy using sentinel lymph node (SLN) acquired lymphocytes has also 
been investigated in two different studies with CRC patients. In a pilot study, Karlsson et 
al. (2010) reinfused SLN acquired CD4+ Th1-lymphocytes expanded ex vivo in 16 
patients with CRC (5 patients with stage II CRC and characteristics of high-risk tumour; 
2 with stage III; and 9 with stage IV CRC). All patients with stage IV disease responded 
to treatment, four with stable disease, one with a partial response, and four with complete 
tumour regression. In addition, the median survival of these 9 stage IV CRC patients was 
2.6 years compared with 0.8 years of conventionally treated controls. Four of stage II 
patients and all stage III patients were classified as stable disease. None of the patients 
experienced adverse side-effects (Karlsson et al., 2010).  More recently, a phase I/II 
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study involving 71 stage I-IV CRC patients subjected to surgery demonstrated that 
transfusion of SLN-T lymphocytes expanded ex vivo was not associated with significant 
toxicity and represents a safe adjuvant immunotherapy. In addition, evaluation of the 
clinical response in stage IV patients revealed that the 24-month survival rate of the 
treated group was significantly higher than that of the control group (55.6% versus 
17.5%), and the median OS was 28 and 14 months, respectively (Zhen et al., 2015). 
These two studies demonstrated that SLN-T lymphocyte is a viable and safe 
immunotherapy option for patients with advanced CRC. 
The antitumour potential of the adoptive therapy can be improved with genetic 
engineered T-cells expressing TCRs with high-affinity to tumour-associated antigens 
(TAA). A disadvantage of this approach is that these TCRs are MHC-restricted and thus 
limited to patients with the corresponding MHC haplotype. An alternative approach is the 
use of chimeric antigen receptors (CARs), which are composed of an extracellular 
TAA-specific single-chain antibody variable fragment (scFv) linked through hinge and 
transmembrane domains to an intracellular T-cell signalling domain. CARs can mediate 
non-MHC-restricted recognition of tumour antigens on the surface of a malignant cell. 
This approach, using CD19-targeted CAR T-cells, has demonstrated great success in 
the treatment of hematologic malignancies such as acute lymphoblastic leukemia 
(Maude et al., 2014). In this context, three patients with metastatic CRC refractory to 
conventional treatments have been treated with autologous T-cells genetically 
engineered to express a murine TCR against CEA (Parkhurst et al., 2011). All patients 
experienced decreases in serum CEA levels (74% to 99%) and one patient had a partial 
response with regression of cancer metastatic to the lung and liver. However, the three 
patients developed a severe transient inflammatory colitis which implies a dose limiting 
toxicity. This adverse event was probably due to the expression of CEA on normal 
epithelial cells of colonic mucosa that could have been recognized by CEA-reactive T 
lymphocytes (Parkhurst et al., 2011). A severe adverse event was also reported by 
Morgan et al. (2010) in a CRC patient with metastasis treated with Her2-specific CAR 
T-cells. In this case, minutes after cells infusion the patient experienced severe 
respiratory distress and displayed a dramatic pulmonary infiltrate on chest X-ray, 
eventually resulting in patient’s death in 5 days. The authors hypothesized that this 
patient’ death resulted from a cytokine-release-syndrome caused by the recognition of 
ERBB2 on normal lung epithelial cells by the very high dose of cells administered 
(Morgan et al., 2010). 
In general, the clinical studies using adoptive T-cell therapy reported modest success 
and involved small numbers of CRC patients. Further studies are needed to determine 
the safety and efficacy of this strategy in CRC. 
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4.2.3 Immune Checkpoint Inhibitors 
The immunotherapy approach that is getting most attention and progress in recent years 
is the immune checkpoint blockade. 
Immune checkpoints refer to complex inhibitory pathways that mediate immunological 
self-tolerance and modulate the duration and amplitude of physiological immune 
responses in order to prevent damage of peripheral tissues (Pardoll, 2012). However, it 
is now well established that tumour cells can develop mechanisms to evade the host 
immune system, namely by exploiting these inhibitory checkpoints, thus limiting 
antitumour immune response (Poschke et al., 2011). 
CTLA-4 and PD-1 are two immune checkpoint molecules that downregulate T-cell 
activity and have been intensively studied in several types of cancer such as melanoma 
and NSCLC (Pardoll, 2012). Immunotherapies using antibodies designed to inhibit these 
immune checkpoints are under intense investigation and encouraging clinical results 
have been achieved.  
 
CTLA-4 
As previously described, an immune response against pathogens or tumour cells is 
triggered by the recognition and binding of a TCR to an antigen displayed in the context 
of an MHC molecule on the surface of an APC. An effective immune response requires 
in addition costimulatory signals - typically the interaction of CD28 expressed on T-cells 
with either B7-1 (CD80) or B7-2 (CD86) on the APCs. CD28 signalling induces cytokine 
production (IL-2) and T-cell activation. Once activated, T-cells up-regulate CTLA-4 
transcription and expression in the cell surface, where it is able to bind B7 molecules 
with much more affinity than CD28, thereby preventing CD28 costimulation and T-cell 
activation (Figure 2, Panel A) (Walunas et al., 1994; Krummel & Allison, 1995). 
Furthermore, previous studies have demonstrated that CTLA-4 can also remove B7 
ligands from APCs via transendocytosis (Qureshi et al., 2011). CTLA-4 therefore 
down-modulates the amplitude of early T-cell activation, limiting their antitumour activity 
(Pardoll, 2012). 
The essential role of CTLA-4 in maintaining immunologic tolerance is demonstrated by 
the lethal phenotype of Ctla-4 null mice, which developed early lymphoproliferative 
disease with lymphocytic infiltration into multiple tissues, and died within 3-4 weeks of 
age (Tivol et al., 1995; Waterhouse et al., 1995). In humans, germline heterozygous 
mutations in CTLA-4 gene have been identified in patients with severe immune 
impairments, characterized mainly by dysregulation of FoxP3+ Treg cells, hyperactivation 
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of effector T-cells and lymphocytic infiltration of target organs (Kuehn et al., 2014; 
Schubert et al., 2014). 
In line with these data, Leach et al. (1996) showed that the in vivo administration of 
antibodies against CTLA-4 induced rejection of pre-stablished tumours in mouse and 
provided immunity against secondary exposure to tumour cells. These pre-clinical data 
prompted the development of two monoclonal antibodies targeting CTLA-4 – 
ipilimumab and tremelimumab – in order to increase antitumour immune response 
(Figure 2, Panel A). Ipilimumab was the first checkpoint inhibitor to be approved by FDA 
(2011) for the treatment of unresectable or metastatic melanoma (Hodi et al., 2010). 
Despite the successful clinical results achieved with CTLA-4 inhibitors in melanoma, 
clinical studies with CRC patients have been quite disappointing. A phase II study with 
the anti-CTLA-4 antibody tremelimumab in patients with refractory metastatic CRC did 
not demonstrate significant antitumour activity. In fact, from the 45 patients evaluable for 
response, 43 received just one dose of tremelimumab due to disease progression, and 
only one patient had a partial response and received a total of five doses, upon which 
disease progression was documented. Thirty of the patients (63.8%) experienced 
adverse events, including diarrhea, colitis, fatigue, nausea, pyrexia, vomiting, skin rash, 
and autoimmune thrombocytopenia (Chung et al., 2010).  
 
PD-1 
In contrast to CTLA-4, which regulates the early activation of T-cells predominantly in 
the lymph nodes, PD-1 suppresses T-cells primarily in peripheral tissues at a later phase 
of the immune response (Pardoll, 2012). PD-1 is expressed on the surface of activated 
and exhausted T-cells, B-cells, NK cells, and macrophages. It interacts with two ligands, 
programmed death ligand-1 (PD-L1) and PD-L2, which are expressed on the surface of 
APCs and malignant cells (Figure 2, Panel B) (Baumeister et al., 2016).  
Blockade of this pathway using monoclonal antibodies directed to PD-1 or PD-L1 has 
demonstrated favorable clinical responses in several type of tumours, including 
melanoma, NSCLC, renal-cell carcinoma, Hodgkin’s lymphoma, and head and neck 
cancers (Brahmer et al., 2012; Topalian et al., 2012; Ferris et al., 2016; Younes et al., 
2016). Based on these data, since 2014 two anti-PD-1 monoclonal antibodies –
nivolumab and pembrolizumab – have been approved by FDA as treatment options in 
several malignancies. In addition, in 2015 the combination of ipilimumab and nivolumab 
was approved by FDA for the treatment of patients with advanced melanoma (Larkin et 
al., 2015). 
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In what concerns CRC, initial clinical trials have demonstrated very low response rates 
to PD-1 inhibitors. A phase I trial to evaluate the safety, tolerability and pharmacokinetics 
of nivolumab included patients with advanced metastatic melanoma (n=10), CRC (n=14), 
castrate resistant prostate cancer (n=8), NSCLC (n=6), and renal cell carcinoma (n=1). 
Two patients (melanoma, renal cell carcinoma) exhibited partial responses and one 
patient with CRC had a complete response which persisted 3 years after treatment 
(Brahmer et al., 2010; Lipson et al., 2013). Nivolumab was well tolerated, with only one 
serious adverse event documented (inflammatory colitis). Topalian et al. (2012), in a 
study with 296 patients with different types of cancer, observed partial or complete 
responses in those with NSCLC (18%), melanoma (28%) and renal-cell cancer (27%), 
but no objective responses were reported in CRC and prostate cancer patients. Grade 3 
or 4 treatment-related adverse events occurred in 14% of the patients and three of them 
died from pneumonitis. Similar results were observed in a phase I trial with an anti-PD-L1 
antibody, with objective responses reported in patients with metastatic NSCLC, 
melanoma, renal-cell cancer and ovarian cancer, but not in CRC, gastric, pancreatic nor 
breast cancer patients (Brahmer et al., 2012). 
Interestingly, a recent study has demonstrated that the microsatellite instability status of 
the tumour could predict the clinical benefit of the immune checkpoint blockade (Le et 
al., 2015). This phase II trial, designed to evaluate the clinical activity of pembrolizumab 
(anti-PD-1), found that patients with mismatch repair (MMR)-deficient CRC (n=10) had 
significantly improved response rates (40%) and immune-related PFS rates (78%) than 
those who had MMR-proficient CRC (0% and 11%, respectively). More importantly, in 
those patients with MMR-deficient CRC, the median PFS and median OS were not 
reached contrasting with the cohort of patients with MMR-proficient tumours, in which 
the median PFS was 2.2 months and the median OS was 5.0 months. The rationale 
behind this study was that tumours with MMR deficiency would exhibited a large number 
of mutations. These generate more neoantigens resulting in a tumour that is “more 
visible” to patient’s immune system. Indeed, whole-exome sequencing revealed a mean 
of 1782 somatic mutations per tumour in patients with MMR deficiency, contrasting to 73 
in patients with MMR-proficient tumours. In addition, membranous PD-L1 expression 
was only observed in patients with MMR-deficient cancers. Remarkably, additional 
analysis of the single CRC patient with a durable complete response to nivolumab in the 
study by Brahmer et al. (2010) previously mentioned revealed that the tumour was 
MMR-deficient (Lipson et al., 2013). These results are in agreement with other studies 
indicating that MSI tumours present a microenvironment rich in activated Th1 cells and 
cytotoxic T lymphocyte (CTL) (Dolcetti et al., 1999; Smyrk et al., 2001; Llosa et al., 2015). 
Llosa et al. (2015) have also detected an overexpression of several immune checkpoints 
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in the MSI tumours microenvironment (including PD-1, PD-L1, and CTLA-4, among 
others) as compared to microsatellite-stable tumours. The authors conclude that MSI 
tumours upregulate inhibitory molecules to compensate the CTL-rich microenvironment, 
thereby preventing elimination by the immune system. 
Taken together these data suggests that the subset of CRC patients with MSI could be 
a particularly good candidate to immunotherapy with checkpoint inhibitors. Currently, 
several ongoing clinical trials are evaluating the clinical activity of combinations of 
ipilimumab with PD-1/PD-L1 antibodies as well as combinations of different checkpoint 
inhibitors with chemotherapy or radiation in CRC.  
 
 
 
Figure 2: Immune checkpoints (CTLA-4 and PD-1) signaling in an antitumour 
immune response. CTLA-4 is expressed by T-cells shortly after their activation 
and competes with CD28 for B7 costimulatory molecules on DCs. CTLA-4 binding 
to B7 provides inhibitory signals to T-cells. Antibody blockade of CTLA-4 (e.g. 
ipilimumab) prevents this inhibition (Panel A). PD-1 is expressed by T-cells during 
long-term antigen exposure and its interaction with PD-L1 or PD-L2 on tumour cells 
suppresses the effect of the TCR on T-cell activation. Blockade of PD-1 or PD-L1 
with antibodies (e.g. nivolumab or atezolizumab, respectively) releases the 
inhibition over TCR signaling, allowing T-cell activation (Panel B). Adapted from 
Ribas et al. (2005). 
A
B
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5. Discussion and Conclusions 
 
To date, immunotherapy in CRC demonstrated modest clinical benefits, but several trials 
are ongoing in order to evaluate additional immune-based therapies either as single 
agents or in combination regimens. 
Active specific immunotherapy using therapeutic cancer vaccines has been investigated 
over decades in different types of tumors, but only Sipuleucel-T has been approved by 
the FDA for the treatment of prostate cancer patients. This reflects a possible limiting 
step of cancer vaccines which is its reliance on previous identification of tumour antigens 
that are able to elicit an effective cytotoxic T-cell response against cancer cells. The ideal 
antigens must be highly expressed on tumour cells but not in healthy tissues, and must 
have minimally homology with other host proteins to ensure specificity of the response 
and reduce off-target toxicities.  
In what concerns the adoptive T-cell therapy, clinical trials performed in CRC patients 
revealed that more studies are required to improve both safety and efficacy of this 
strategy. Thus far, adoptive T-cell therapy using CD-19-targeted CAR T-cells showed 
great success in the treatment of B-cell malignances such as acute lymphoblastic 
leukemia. CD19 is a suitable antigen because it is expressed on a broad range of 
differentiated B-cells, but is not present on hematopoietic stem cells or other cell types 
(Khalil et al., 2016). The selection of similar antigens in solid tumors could be challenging, 
not only because these malignancies are in general more heterogeneous than liquid 
tumors, but also because target antigens are more likely to be also expressed in normal 
tissues (Khalil et al., 2016). Concerning CRC, some studies have identified other 
molecules that may be potentially suitable as cancer-specific antigens, like GUCY2C and 
OR7C1 (Snook et al., 2011; Morita et al., 2016). 
Immune checkpoint inhibitors are the immunotherapy agents that are receiving most 
attention in the last few years. Monoclonal antibodies against CTLA-4, PD-1 and PD-L1 
have been evaluated in several trials and approved to be used in the clinical setting for 
the treatment of melanoma and NSCLC, among other tumours. In CRC, studies have 
demonstrated that the subgroup of patients with microsatellite instable tumors benefits 
from therapy with pembrolizumab (PD-1 inhibitor) and, based on this finding, a phase II 
study (NCT02460198) and a phase III study (NCT02563002) are underway in 
MMR-deficient advanced CRC to confirm such results. However, this group represents 
a small subset of patients, so clinical trials are currently in progress to evaluate other 
immunotherapy agents that could have an impact on clinical outcome also in CRC 
patients with microsatellite stable tumours. In particular, the combination of immune 
checkpoint inhibitors with other anticancer agents that may increase tumour sensitive to 
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immunotherapy is being tested. Recently, preliminary data from a phase Ib trial 
(NCT01988896) demonstrated for the first time a clinical value for PD-L1 inhibition in 
patients with microsatellite-stable tumours (Bendell et al., 2016). This study is evaluating 
the safety and clinical activity of atezolizumab (anti-PD-L1 antibody) in combination with 
cobimetinib (MEK inhibitor) in patients with locally advanced or metastatic solid tumours. 
The rationale underlying this approach was based on preclinical studies which 
demonstrated that targeted inhibition of MEK results in MHC class I upregulation on 
cancer cells, promotes intratumoral T-cell infiltration, and enhances anti-PD-L1 activity. 
Provisional results from this trial showed that from the 23 CRC patients, 4 had a partial 
response and 5 had stable disease; most importantly, three of the responders had MSS 
tumours.  
Similarly, numerous combination strategies comprising agents with different 
mechanisms of action are being investigated in order to achieve higher response rates 
and prolonged overall survival. For instance, CTLA-4 and PD-1 inhibitors have been 
used together in patients with metastatic melanoma with positive results (Larkin et al., 
2015). Checkpoint inhibitors may also exhibit synergistic effects when combined with 
antigen-directed therapies (e.g. cancer vaccines) and even with conventional cytotoxic 
agents or radiation. Although these last two anticancer therapies were initially considered 
immunosuppressive, it is presently known that some agents can induce an immune 
response. Radiation, for example, by destroying tumor cells, releases antigens that can 
be captured by antigen presenting cells, triggering T-cell activation. Once again, 
checkpoint blockade would prevent inhibition of T-cells activation, thereby allowing for 
an effective anticancer immune response. 
The modest results obtained thus far in studies of CRC immunotherapy could also rely 
on the fact that most of them have been carried out in patients with advanced-stage 
tumours, with a likely compromised immune system that is unable to mount an 
appropriate immune response. It could be speculated, therefore, that the best candidates 
for immunotherapy are patients at initial-stage disease with a risk of recurrence after 
tumour resection. 
 
While cancer immunotherapy has emerged as an important treatment option, it presents 
relevant features that differentiate it from conventional therapies and of which physicians 
should be aware of. In this context, the introduction of checkpoints inhibitors in clinical 
practice revealed a unique toxicity profile known as “immune-related adverse events” 
(irAE) (Wolchok et al., 2009). These irAE are mainly related to inflammatory conditions 
such as dermatitis, colitis, hepatitis, pancreatitis, pneumonitis and hypophysitis, as it 
could be expected from the mechanism of action of immunotherapies. Adverse events 
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can range from moderate to severe but are usually manageable with immunosuppressive 
agents like corticosteroids, which do not seem to alter the antitumor effect of the therapy 
(Sharma & Allison, 2015). Although the profile of irAE observed with CTLA-4 and 
PD-1/PD-L1 inhibitors is comparable, anti-CTLA4 therapy is associated with more 
frequent and severe toxicity. Another important distinction of cancer immunotherapy 
compared to conventional treatments has to do with the kinetics of clinical response, 
which comprises three progressive steps (Hoos et al., 2010): firstly, the immune 
activation and proliferation of T-cells occurs; secondly, after weeks to months, an 
antitumour immune response becomes evident; thirdly, months after the initial treatment, 
an effect on patient survival could be evident. This means that, contrasting with 
conventional cytotoxic therapies that directly attack cancer cells, clinical response to 
immunotherapy may take several months to be detectable. In fact, some patients may 
even experience an initial phase of tumour and/or metastatic lesions growth due to 
infiltration by immune cells. All these aspects are disregarded by the Evaluation Criteria 
in Solid tumors (RECIST) traditionally used to evaluate the response to cytotoxic agents, 
so new criteria, better adapted to immunotherapy, have been established to incorporate 
these findings (the immune-related response criteria - irRC) (Hoos et al., 2010).  
 
In conclusion, immunotherapy represents a novel and promising approach to fight 
cancer. While individual agents have shown high response rates and durable response 
in some types of cancer, it is likely that in the future combined strategies will improve 
clinical outcomes and be effective in the treatment of other types of cancer, such as 
colorectal cancer. 
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